期刊文献+

阿托伐他汀与血管钙化的研究 被引量:3

Study on atorvastatin and vascular calcification
原文传递
导出
摘要 血管钙化是心血管疾病如动脉粥样硬化、肾病、收缩性高血压、糖尿病等共同的病生理基础,主要是血管壁钙盐异常沉积,与血管粥样硬化及血管顺应性降低密切相关。对血管钙化机制和治疗方法研究对临床会有极大的帮助。而近年来大量研究证明,他汀类药物不仅有降脂作用,具有抑制血管平滑肌成骨样分化、抗炎抗氧化、凋亡等机制,可能对防御或治疗血管钙化也有一定的影响,作者选具有代表性的他汀类药物—阿托伐他汀,对血管钙化影响的研究进展做综述。 Vascular calcification is the common physiological basis of cardiovascular diseases such as atherosclerosis,kidney disease,systolic hypertension,diabetes and other,which is mainly abnormal calcium salt deposition in the blood vessel walls,and it is closely related to vascular atherosclerosis and decreased vascular compliance. Research on vascular calcification mechanism and treatment method has great help on clinical treatment. In recent years,a large number of studies have shown that statins not only have lipid- lowering effect,with the mechanism of inhibiting osteogenic differentiation of vascular smooth muscle,anti-inflammatory,antioxidants and anti-apoptosis,but also have a certain influence on the prevention or treatment of vascular calcification. This article reviews the research progress of effect on vascular calcification from a representative sample of statins-atorvastatin.
作者 陈慧敏 杨英
出处 《职业与健康》 CAS 2017年第2期271-273,共3页 Occupation and Health
基金 内蒙古自然科学基金项目(2014MS0345)
关键词 阿托伐他汀 血管钙化 动脉硬化 Atorvastatin Vascular calcification Atherosclerosis
  • 相关文献

参考文献2

二级参考文献45

  • 1Tsuchihashi K, Takizawa H, Torii T, Ikeda R, Nakahara N, Yuda S, et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal disease. Nephron 2000; 84: 13–20.
  • 2London GM, Marchais SJ, Guerin AP, Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525–31.
  • 3Parfitt AM. Soft-tissue calcification in uremia. Arch Intern Med 1969; 124: 544–56.
  • 4Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044–59.
  • 5Iribarren C, Sidney S, Sternfeld B, Browner WS. Calcification of the aortic arch: risk factor and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA 2000; 283: 2810–5.
  • 6Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Addahi JM, et al. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Circulation 1996; 94: 1175–92.
  • 7Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 2006; 26: 1423–30.
  • 8Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117: 2938–48.
  • 9Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001; 89: 1147–54.
  • 10Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23: 489–94.

共引文献16

同被引文献19

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部